Angela M Sousa1, Giovanna M C Rosado2, Jose de S Neto3, Gabriel M N Guimarães4, Hazem A Ashmawi5. 1. Cancer Institute of the State of Sao Paulo and Anesthesia Division from Hospital das Clínicas of the University of São Paulo. Av. Dr. Eneas Carvalho de Aguiar, 255, 8th floor, Cerqueira César, São Paulo, SP, CEP 05403-000, Brazil. Electronic address: angela.sousa@hc.fm.usp.br. 2. Cancer Institute of the State of Sao Paulo and Anesthesia Division from Hospital das Clínicas of the University of São Paulo. Av. Dr. Eneas Carvalho de Aguiar, 255, 8th floor, Cerqueira César, São Paulo, SP, CEP 05403-000, Brazil. Electronic address: giovannamrcr@yahoo.com.br. 3. Cancer Institute of the State of Sao Paulo and Anesthesia Division from Hospital das Clínicas of the University of São Paulo. Av. Dr. Eneas Carvalho de Aguiar, 255, 8th floor, Cerqueira César, São Paulo, SP, CEP 05403-000, Brazil. Electronic address: jose_santana@icloud.com. 4. Cancer Institute of the State of Sao Paulo and Anesthesia Division from Hospital das Clínicas of the University of São Paulo. Av. Dr. Eneas Carvalho de Aguiar, 255, 8th floor, Cerqueira César, São Paulo, SP, CEP 05403-000, Brazil. Electronic address: gabrielmng@gmail.com. 5. Anesthesia Division of Hospital das Clínicas da Universidade de São Paulo, Av. Dr. Eneas Carvalho de Aguiar, 255, 8th floor, Cerqueira César, São Paulo, SP, CEP 05403-000, Brazil. Electronic address: hazem.ashmawi@gmail.com.
Abstract
STUDY OBJECTIVE: The aim of this study is to compare the analgesic effect of intravenous infusion of magnesium sulfate to ketorolac during laparoscopic surgeries. DESIGN: Double-blind randomized controlled trial. SETTING: University-affiliated teaching hospital. PATIENTS: Sixty women submitted to laparoscopic gynecologic oncology surgeries. INTERVENTIONS:Intravenous ketorolac 30 mg in bolus followed by saline infusion (group K), intravenous magnesium sulfate 20 mg/kg in bolus followed by magnesium 2 mg kg(-1) h(-1) (group M) or intravenous saline solution 20 mL in bolus followed by saline infusion during the entire procedure (group S). MEASUREMENTS: Postoperative pain, nausea, vomiting, sedation, opioid consumption, time to first dose of analgesic. MAIN RESULTS:Magnesium sulfate reduced opioid consumption compared with placebo in the postoperative, but not in the intraoperative, period. Nausea, not vomiting, was reduced in ketorolac but not in the magnesium group. Pain intensity was higher in placebo than in the other 2 groups during all periods of observation. In the first 60 minutes, pain intensity was lower in the magnesium than in the ketorolac or the placebo group. CONCLUSION:Intraoperative magnesium sulfate improves postoperative pain control, acting as an opioid-sparing adjuvant, and is similar to ketorolac 30 mg administered in the beginning of surgery.
RCT Entities:
STUDY OBJECTIVE: The aim of this study is to compare the analgesic effect of intravenous infusion of magnesium sulfate to ketorolac during laparoscopic surgeries. DESIGN: Double-blind randomized controlled trial. SETTING: University-affiliated teaching hospital. PATIENTS: Sixty women submitted to laparoscopic gynecologic oncology surgeries. INTERVENTIONS: Intravenous ketorolac 30 mg in bolus followed by saline infusion (group K), intravenous magnesium sulfate 20 mg/kg in bolus followed by magnesium 2 mg kg(-1) h(-1) (group M) or intravenous saline solution 20 mL in bolus followed by saline infusion during the entire procedure (group S). MEASUREMENTS: Postoperative pain, nausea, vomiting, sedation, opioid consumption, time to first dose of analgesic. MAIN RESULTS:Magnesium sulfate reduced opioid consumption compared with placebo in the postoperative, but not in the intraoperative, period. Nausea, not vomiting, was reduced in ketorolac but not in the magnesium group. Pain intensity was higher in placebo than in the other 2 groups during all periods of observation. In the first 60 minutes, pain intensity was lower in the magnesium than in the ketorolac or the placebo group. CONCLUSION: Intraoperative magnesium sulfate improves postoperative pain control, acting as an opioid-sparing adjuvant, and is similar to ketorolac 30 mg administered in the beginning of surgery.
Authors: Hany Mahmoud Yassin; Ahmed Tohamy Abdel Moneim; Ahmed Sherin Mostafa Bayoumy; Hasan Metwally Bayoumy; Sameh Galal Taher Journal: Anesth Essays Res Date: 2017 Oct-Dec
Authors: Waynice N Paula-Garcia; Gustavo H Oliveira-Paula; Hans Donald de Boer; Luis Vicente Garcia Journal: BMC Anesthesiol Date: 2021-03-27 Impact factor: 2.217